Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

A Comparison of Coated and Uncoated Stents in Renal Artery Treatment. (GREAT)

This study has been completed.
Information provided by:
Cordis Corporation Identifier:
First received: October 6, 2005
Last updated: August 5, 2008
Last verified: August 2008
The primary objective of this study is to compare the safety and performance of the Palmaz Genesis™ balloon expandable stent, with or without sirolimus coating in the treatment of renal artery stenosis, measured at 6 months follow up via angiography.

Condition Intervention Phase
Renal Artery Stenosis
Device: Sirolimus-eluting Palmaz Genesis peripheral stent
Phase 2

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Palmaz Genesis Peripheral Stainless Steel Balloon Expandable Stent, Comparing a Sirolimus Coated Versus an Uncoated Stent in REnal Artery Treatment.

Resource links provided by NLM:

Further study details as provided by Cordis Corporation:

Primary Outcome Measures:
  • assessment of the angiographical in-stent minimal lumen diameter [ Time Frame: 6-months follow up ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:
  • clinical primary patency [ Time Frame: discharge, 1, 6 and 12 months post-procedure ] [ Designated as safety issue: Yes ]
  • procedural success [ Time Frame: post-procedure ] [ Designated as safety issue: Yes ]
  • worsening renal function [ Time Frame: 30 days, 6 months, 12 months ] [ Designated as safety issue: Yes ]
  • change in blood pressure measurement [ Time Frame: 30 days, 6 months, 12 months ] [ Designated as safety issue: Yes ]
  • significant embolic events causing end-organ damage [ Time Frame: 30 days, 6 months, and 12 months ] [ Designated as safety issue: Yes ]

Enrollment: 105
Study Start Date: November 2001
Study Completion Date: July 2005
Primary Completion Date: November 2002 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1
Sirolimus-eluting Palmaz Genesis peripheral stent
Device: Sirolimus-eluting Palmaz Genesis peripheral stent
treatment of renal artery stenosis with a renal stent
Other Name: Palmaz Genesis Stent

Detailed Description:

Multi-center, prospective, controlled, non-randomized investigational feasibility study. One hundred (100) patients with de novo or restenotic renal artery lesions consisting of >= 50% stenosis and reference vessel of >= 4.0 to <= 8.0 mm in diameter will be sequentially included, 50 without sirolimus coating, followed by 50 with sirolimus coating Palmaz GenesisTM. Patients will be followed for 24 months post-procedure, with all patients having clinical assessments at discharge, 1,6, 12 and 24 months. This study will be conducted at twelve investigational sites.

It is anticipated that the total length of time required to complete the study will be 46 months.


Ages Eligible for Study:   30 Years and older   (Adult, Senior)
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Clinical indication for renal artery revascularization of atherosclerotic renal artery stenosis >=50% as measured by operator or estimated original vessel diameter, based on healthy vessel segment and contralateral side.
  2. The reference vessel renal artery must be >= 4mm and <= 8 mm by visual estimate.
  3. The patient must have a baseline serum creatinine of <= 5.0 mg/dl.

Exclusion Criteria:

  1. Total occlusion of the renal artery.
  2. Lesions which would require more than 2 stents.
  3. Lesions which are in arteries to transplanted or bypassed kidneys.
  4. Abdominal aortic aneurysm > 4.0 cm in diameter.
  5. Patients with ASA classification >=4.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00235157

Hopital Européen Georges Pompidou
Paris, France, 75 015
Universitätskliniken Köln
Köln, Germany, 50931
Erasmus MC Rotterdam
Rotterdam, Netherlands, 3000 CA
Sponsors and Collaborators
Cordis Corporation
Principal Investigator: Markus Zähringer, MD Universitätskliniken Köln
Principal Investigator: Marc Sapoval, MD Hopital Européen Georges Pompidou
Principal Investigator: Peter M Pattynama, MD Erasmus MC Rotterdam
  More Information

Responsible Party: Dr. Hans-Peter Stoll, Director Clinical Affairs, Cordis Identifier: NCT00235157     History of Changes
Other Study ID Numbers: EE01-01 
Study First Received: October 6, 2005
Last Updated: August 5, 2008
Health Authority: Germany: Ethics Commission

Additional relevant MeSH terms:
Renal Artery Obstruction
Kidney Diseases
Urologic Diseases
Arterial Occlusive Diseases
Vascular Diseases
Cardiovascular Diseases
Anti-Bacterial Agents
Anti-Infective Agents
Antibiotics, Antineoplastic
Antineoplastic Agents
Antifungal Agents
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs processed this record on October 26, 2016